Category Archives: Potential Treatments

Upcoming ASCO abstracts

There are 14 abstracts for the upcoming ASCO that have ALK in the title. But only 6 look like they are likely to be broadly applicable to people on this board. I will be posting summaries over the next week … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Entrectinib phase 1-2 trial update

Entrectinib was tested in 119 patients with three kinds of mutations: NTRK+, ALK, and ROS1. Efficacy data was reported for 24 patients. For ALK there appear to have been 5 patients, and 57% of them had a tumor response (presumably … Continue reading

Posted in Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects | Leave a comment

Ensartinib (X396) trial update

63 patients in trial but only 35 are ALK+, NSCLC, and treated at 200 to 250 mg daily. Of those, 8 were ALK inhibitor naive, 7 (88%) had an objective response. 19 patients had received Crizotinib but not another ALK … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects, X-396 - ensartinib from Xcovrery | Leave a comment

Additional Brigatinib info

Ariad has posted a new presentation from European Lung Cancer Conference on their website for a limited time. Pages 7-13 are most relevant. Page 8 shows a breakdown of how patients ┬áresponded by dose. 90 mg had a ORR of … Continue reading

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Ariad announces start of Phase 3 trial

Ariad today announced the initiation of a first line phase 3 trial comparing Brigatinib with Crizotinib. Patients must be ALK inhibitor naive. They are planning to enroll around 270 patients. They expect to complete enrollment in 2018. Of interest, the … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research | Leave a comment

Brigatinib update

Thanks to Dave for pointing this out. This info can be found on Ariad’s site under Investors, presentations. It’s from the Cowan Healthcare presentation which may only be available for a few weeks. The relevant info is on pages 15-16. … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research | Leave a comment

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Phase 1 trial of ASP3026

The first posting about this Phase 1 trial in ClinicalTrials.gov was in 1-25-2011. The trial number is NCTO1284192. It was conducted at 6 hospitals. On March 10, 2016 an article was published that said the dose escalation part of trial … Continue reading

Posted in ASP3026 from Astellas, Lung cancer, Potential Treatments, Research | Leave a comment

Long term phase 1 data for Ceritinib

On March 10 an article was published on the long term results of a phase 1 trial of Ceritinib. The trial enrolled 255 patients from January 2011 and July 2013 of whom 246 had ALK + lung cancer. Data cutoff … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment, Side Effects | Leave a comment

Crizotinib approved for ROS1 + lung cancer

On March 11 the FDA approved the selling of Crizotinib for patients with ROS1 mutations in lung cancer. The ORR was 66% and the median DOR was 18.3 months. Safety profile was similar to that in ALK + patients. http://www.businesswire.com/news/home/20160311005839/en/XALKORI%C2%AE-crizotinib-Approved-U.S.-FDA-Treatment-Patients

Posted in crizotinib - Xalkori from Pfizer, Lung cancer, Regulatory applications & approvals | Leave a comment